PF-08046045 is under clinical development by Pfizer and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase I drugs for Cutaneous T-Cell Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PF-08046045’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PF-08046045 overview
PF-08046045 (SGN-35T) is under development for the treatment of relapsed or refractory lymphomas including classical Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL), systemic anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma and primary cutaneous lymphomas (PCL) and advanced solid tumor. The therapeutic candidate is a CD30-directed antibody-drug conjugate, with a tripeptide linker and is administered through intravenous route.
Pfizer overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of PF-08046045’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.